Document Detail


Very early viral kinetics on interferon treatment in chronic hepatitis C virus genotype 4 infection.
MedLine Citation:
PMID:  18672537     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: Interferon (IFN)-resistant hepatitis C virus strains limit efficacy of antiviral combination therapy in patients infected with genotypes 1 and 4. A single test dose of IFN was useful to identify non-responders to IFN-alpha2b/ribavirin (RBV) or likely non-responders to pegylated (PEG)-IFN-alpha2a/RBV therapy in genotype 1 patients. Our aim was to investigate this approach in genotype 4 patients. METHODS: Viral load was measured in 46 patients before and 24 h after 10 megaunits (MU) IFN-alpha2b, and before and during 2 weeks of daily 5 MU IFN-alpha2b administration. Thereafter, patients received 48 weeks combination therapy with either 180 microg PEG-IFN-alpha2a/week (n=33), 1.5 microg/kg PEG-IFN-alpha2b/week (n=7) or 5 MU IFN-alpha2b/2 days (n=6), along with 1-1.2g RBV/day. For prediction analysis the largest group (PEG-IFN-alpha2a) was evaluated only. RESULTS: Median 24 h log10 change after 10 MU IFN-alpha2b was 1.15 (range 0.08-2.48) and after 5 MU IFN-alpha2b was 0.81 (-0.12-2.22; P<0.0001). Log10 changes after 2 weeks on 5 MU IFN-alpha2b daily and 24 h after 10 MU were the best predictors of early virological response (defined by negativity of a standard qualitative PCR) to PEG-IFN-alpha2a/RBV combination therapy (area under curve [AUC]=0.97; P<0.001, receiver operating characteristics), 24 h log10 change after 10 MU was the best predictor of sustained virological response (SVR; AUC=0.91, P=0.001). CONCLUSION: As in genotype 1 patients, there is large variation in IFN responsiveness, including the presence of resistant strains, in genotype 4 patients. A 24 h log10 change after 10 MU IFN-alpha2b is an excellent predictor of SVR on PEG-IFNalpha2a/RBV combination therapy. This test may be useful to obtain homogeneous groups for clinical studies and could help in clinical decision making.
Authors:
Wolfgang Jessner; Michael Gschwantler; Elisabeth Formann; Calin Gurguta; Thomas Watkins-Riedel; Friedrich Wrba; Peter Ferenci
Related Documents :
2182407 - Prospective randomized trial of topical alpha-interferon (alpha-interferon gels) for th...
16021867 - Use of hydroxyurea in heavily pretreated patients with hiv infection.
11434597 - Treatment of patients with chronic hepatitis c not responding to interferon with high-d...
15759817 - A randomized, controlled, clinical study of thymosin alpha-1 versus interferon-alpha in...
1810557 - Long-term results after right ventricular outflow tract reconstruction with porcine bio...
23383747 - A comparative study of the effectiveness of intense pulsed light wavelengths (650 nm vs...
Publication Detail:
Type:  Clinical Trial; Journal Article    
Journal Detail:
Title:  Antiviral therapy     Volume:  13     ISSN:  1359-6535     ISO Abbreviation:  Antivir. Ther. (Lond.)     Publication Date:  2008  
Date Detail:
Created Date:  2008-08-04     Completed Date:  2008-09-12     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9815705     Medline TA:  Antivir Ther     Country:  England    
Other Details:
Languages:  eng     Pagination:  581-9     Citation Subset:  IM    
Affiliation:
Department of Internal Medicine III, Gastroenterology and Hepatology, Vienna Medical University, Vienna, Austria.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Antiviral Agents* / pharmacology,  therapeutic use
Drug Therapy, Combination
Female
Genotype
Hepacivirus* / classification,  drug effects,  genetics,  physiology
Hepatitis C, Chronic / drug therapy*,  virology
Humans
Interferon Alfa-2a* / administration & dosage,  therapeutic use
Interferon Alfa-2b* / administration & dosage,  therapeutic use
Male
Middle Aged
Polyethylene Glycols* / administration & dosage,  therapeutic use
RNA, Viral / blood
Ribavirin* / administration & dosage,  therapeutic use
Time Factors
Treatment Outcome
Viral Load
Chemical
Reg. No./Substance:
0/Antiviral Agents; 0/Polyethylene Glycols; 0/RNA, Viral; 0/peginterferon alfa-2a; 0/peginterferon alfa-2b; 36791-04-5/Ribavirin; 76543-88-9/Interferon Alfa-2a; 99210-65-8/Interferon Alfa-2b

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Long-term follow-up of lamivudine treatment in patients with severe acute exacerbation of hepatitis ...
Next Document:  Effect of lopinavir/ritonavir monotherapy on quality of life and self-reported symptoms among antire...